• English

上海凡默谷信息技術有限公司

上海凡默谷信息技術有限公司

上海市

021-50263208
客服微信:ipharmogo

周一至周五 9:00~19:00

解決方案
  • 首頁
  • 關于我們
    • 公司簡介
    • 典型用戶
    • 合作伙伴
  • 新聞資訊
    • 培訓通知
    • 公司動態
  • 產品中心
    • GastroPlus
    • ADMET Predictor
    • DDDPlus
    • 其他產品
  • 培訓中心
    • 視頻匯總
    • 技術視頻
    • 凡默谷技術文章
    • 使用FAQ
    • 歷年文獻匯總
  • 在線申請
  • 聯系我們
  • 首頁
  • 關于我們
    • 全部
    • 公司簡介
    • 典型用戶
    • 合作伙伴
  • 新聞資訊
    • 全部
    • 培訓通知
    • 公司動態
  • 產品中心
    • 全部
    • GastroPlus
    • ADMET Predictor
    • DDDPlus
    • 其他產品
  • 培訓中心
    • 全部
    • 視頻匯總
    • 技術視頻
    • 凡默谷技術文章
    • 使用FAQ
    • 歷年文獻匯總
  • 在線申請
  • 聯系我們
GastroPlus在FDA、EMA等法規部門的應用文章列表(2016-2020)
  1. 您現在所在位置:
  2. 網站首頁
  3. GastroPlus系列文章匯總

GastroPlus在FDA、EMA等法規部門的應用文章列表(2016-2020)

2021-03-14 16:54:31

導  讀

凡默谷技術部精選了2016-2020年10月GastroPlus在FDA、EMA、EPA等法規部門的應用文章。

其中序號01-10的文章是2019年8月-2020年10月新增文章。

希望對您的業務或專業學習有所幫助。內容如下:


01.  使用生理藥代動力學吸收模型建立奧司他韋在成人和兒童人群中的生物等效性溶出安全空間

Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Oseltamivir in Adult and Pediatric Populations

Lei Miao, Youssef M. Mousa, Liang Zhao, Kimberly Raines, Paul Seo,Fang Wu. The AAPS Journal. volume 22, Article number: 107 (2020).IF= 3.737


02.  人工合成膜在建立睪丸激素透皮凝膠生物預測性IVPT中的應用

Application of synthetic membranes in establishing bio-predictive IVPT for testosterone transdermal gel.

Mohamed LA, Kamal N, Elfakhri KH, Ibrahim S, Ashraf M, Zidan AS. Int J Pharm. Volume 586, 30 August 2020, 119572. IF=4.845


03.用于支持藥品開發,生產變更與控制的轉化建模策略的現狀和未來期望:研討會總結報告
Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report.

Pepin XJ, Parrott N, Dressman J, Delvadia PR, Mitri? M, Zhang X, Babiskin AH, Kolhatkar V, Suarez-Sharp S. J Pharm Sci. May 2020.IF=2.997


04.食品成分的安全性評估:毒性動力學方法的實用性和相關性


Food ingredient safety evaluation: Utility and relevance of toxicokinetic methods.

Kabadi SV, Zang Y, Fisher JW, Smith N, Whiteside C, Aungst J. Toxicol Appl Pharmacol. Volume 382, 1 November 2019, 114759. IF=3.347


05.具有生物預測性的體外方法:研討會總結報告


In Vitro Biopredictive Methods: A Workshop Summary Report.

Pepin XJ, Dressman J, Parrott N, Delvadia P, Mitra A, Zhang X, Kolhatkar V, Seo P, Taylor LS, Sj?gren E, Butler JM, Kostewicz ES, Tannergren C, Koziolek M, Kesisoglou F, Dallmann A, Zhao Y, Suarez-Sharp S. J Pharm Sci. September 2020. IF= 2.997


06.通過體外溶出曲線相似性支持藥品的質量評估:內容,如何應用,何時應用—研討會總結報告


In Vitro Dissolution Profiles Similarity Assessment in Support of Drug Product Quality: What, How, When—Workshop Summary Report.

Suarez-Sharp S, Abend A, Hoffelder T, Leblond D, Delvadia PR, Kovacs E, Diaz DA. AAPS J. (2020) 22:74. IF= 3.737


07.   采用生理藥代動力學PBPK模型,評估影響美托洛爾緩釋藥品生物等效性的制劑因素


Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products.

Sumit Basu, Haitao Yang, Lanyan Fang, Mario Gonzalez‐Sales, Liang Zhao, Mirjam N. Trame, Lawrence Lesko, Stephan Schmid.

J Clin Pharmacol. Volume59, Issue9. September 2019 Pages 1252-1263. IF=2.425


08.   采用生理藥代動力學PBPK模型支持眼科懸浮制劑的開發


Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.

Le Merdy M, Tan ML, Babiskin AH, Zhao L. AAPS J. (2020) 22: 26. IF= 3.737


09.   針對口服給藥的建模轉化策略:學術,工業和監管的觀點


Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives

Sandra Suarez-Sharp, Anders Lindahl, Tycho Heimbach, Amin Rostami-Hodjegan, Michael B. Bolger, Siladitya Ray Chaudhuri, Bart Hens. Pharm Res. 2020 May 13;37(6):95. IF= 3.242


10.   通過體外劑量-效應數據整合藥代動力學和體內暴露信息,從而對化學品進行篩選和排序的分層方法


Tiered approaches for screening and prioritizing chemicals through integration of pharmacokinetics and exposure information with in vitro dose-response data.

Leonard JA, Tan YM. Computational Toxicology. Volume 12, November 2019, 100101. CiteScore=2.5


11.   固定劑量復方藥品的開發”研討會報告:考慮胃腸生理學的影響和整體發展戰略


“Development of Fixed Dose Combination Products” Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy.

Hens B, Corsetti M, Bermejo M, L?benberg R, González PM, Mitra A, Desai D, Chilukuri DM, Aceituno A. AAPS J. Jun 6, 2019. IF= 3.737


12.   采用眼部機制性吸收建模與模擬,理解制劑處方性質對家兔眼部生物利用度的影響-以地塞米松懸浮液為例


Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Le Merdy M, Fan J, Bolger MB, Lukacova V, Spires J, Tsakalozou E, Patel V, Xu L, Stewart S, Chockalingam A, Narayanasamy S, Rouse R, Matta M, Babiskin AH, Kozak D. AAPS J. May 20, 2019. IF=3.737


13.   采用計算機預測的方法開發仿制藥-裝置組合的口服吸入制劑


In silico methods for development of generic drug‐device combination orally inhaled drug products.

Walenga RL, Babiskin AH, Zhao L. CPT Pharmacometrics Syst Pharmacol.May 1, 2019. CiteScore=5.2


14.   建立體外-體內相關的溶出和轉化建模策略-某研討會總結匯總


Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.

Heimbach T, Suarez-Sharp S, Kakhi M, Holmstock N, Olivares-Morales A, Pepin X, Sj?gren E, Tsakalozou E, Seo P, Li M, Zhang X, Lin HP, Mitra A, Morris D, Patel N, Kesisoglou F. AAPS J. Feb 11, 2019. IF=3.737


15.   具有體內預測性的溶出方法和模擬研討會匯總:促進口服藥物制劑處方的開發和口服療效的預測


In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance.

Tsume Y, Patel S, Fotaki N, Bergstrom CAS, Amidon GL, Brasseur JG, Mudie DM, Sun D, Bermejo M, Gao P, Zhu W, Sperry DC, Vertzoni M, Parrott N, Lionberger RA, Kambayashi A, Hermans A, Lu X, Amidon GE.AAPS J. 2018 Sep 6;20(6):100. IF=3.737


16.   膜轉運蛋白體外-計算機預測數據在化學品風險評估和生物醫學研究中的適用性


Capturing the applicability of in vitro-in silico membrane transporter data in chemical risk assessment and biomedical research.

Clerbaux LA, Coecke S, Lumen A, Kliment T, Worth AP, Paini A. Sci Total Environ. 2018 Dec 15;645:97-108. IF=6.551


17.   開發機制性吸收模型,以預測因溶酶體捕獲而導致Tmax較長的速釋弱堿性藥物的PK


Developing a mechanistic absorption model to predict the pharmacokinetics of immediaterelease weak base drugs with a long Tmax by incorporating lysosomal trapping.

Jia Li, Zhongqi Dong, Fang Wu, Ping Zhao, Sue Chih Lee, Paul Seo, Lei Zhang. Drug Metabolism and Pharmacokinetics 33 (2018) S22-S97.IF=2.772


18.   滲透泵藥品的生理藥代動力學PBPK和吸收模型


Physiologically Based Pharmacokinetic and Absorption Modeling for Osmotic Pump Products.

Ni Z, Talattof A, Fan J, Tsakalozou E, Sharan S, Sun D, Wen H, Zhao L, Zhang X. AAPS J. 2017 Jul;19(4):1045-1053. IF=3.737


19.   生理藥代動力學PBPK模型在食物對口服藥物吸收影響的預測性能:現狀


Predictive Performance of Physiologically Based Pharmacokinetic Models for the Effect of Food on Oral Drug Absorption: Current Status.

Li M, Zhao P, Pan Y, Wagner C. CPT Pharmacometrics Syst Pharmacol.2018 Feb;7(2):82-89. CiteScore=5.2


20.   生理藥代動力學PBPK模型對代謝酶介導的藥物相互作用DDI的預測性能


Predictive Performance of Physiologically-Based Pharmacokinetic Models in Predicting Drug-Drug Interactions Involving Enzyme Modulation.

Hsueh CH, Hsu V, Pan Y, Zhao P. Clin Pharmacokinet. 2018 Feb 17.IF=4.604


21.   采用生理藥代動力學吸收模型預測質子泵抑制劑存在時,鹽型-游離堿轉化對普拉格雷HCl藥品生物等效性的影響


Utility of Physiologically Based Pharmacokinetic Absorption Modeling to Predict the Impact of Salt-to-Base Conversion on Prasugrel HCl Product Bioequivalence in the Presence of Proton Pump Inhibitors.

Fan J, Zhang X, Zhao L. AAPS J. 2017: 1-8. IF=3.737


22.   通過整合體外、建模、體內三種方法探討華法林的生物等效性


Integrating in vitro, modeling, and in vivo approaches to investigate warfarin bioequivalence.

Zhang X, Wen H, Fan J, et al. CPT: Pharmacometrics & Systems Pharmacology, 2017. CiteScore=5.2


23.   探索藥品研發中狗和人的差異性II:采用建模與模擬的方法探索制劑因素對環丙沙星狗體內吸收與溶出的影響


Exploring Canine-Human Differences in Product Performance. Part II: Use of Modeling and Simulation to Explore the Impact of Formulation on Ciprofloxacin In Vivo Absorption and Dissolution in Dogs.

Martinez M N, Mistry B, Lukacova V, et al. AAPS J, 2017, 19(3): 712-726.IF=3.737


24.   通過生理藥代動力學PBPK模型對藥物納米顆粒進行建模


Physiologically based pharmacokinetic (PBPK) modeling of pharmaceutical nanoparticles.

Li M, Zou P, Tyner K, et al. AAPS J, 2017: 1-17. IF=3.737


25.  在EMA研討會上關于生理藥代動力學PBPK建模和模擬的資質和結果報告的匯總


Report from the EMA workshop on qualification and reporting of physiologically based pharmacokinetic (PBPK) modeling and simulation.

Zhao P. CPT: pharmacometrics & systems pharmacology, 2017, 6(2): 71-72. CiteScore=5.2


26.  提高藥品質量:美國FDA藥品質量辦公室的科學和研究概述


Advancing pharmaceutical quality: An overview of science and research in the US FDA’s Office of Pharmaceutical Quality.

Fisher A C, Lee S L, Harris D P, et al. International journal of pharmaceutics, 2016, 515(1): 390-402. IF= 4.845


27.   采用機制性吸收模型研究哌甲酯口服緩釋制劑在成人體內的藥動學曲線


Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults.

Yang X, Duan J, Fisher.J. PloS one, 2016, 11(10): e0164641. IF=2.74


28.   采用建模與模擬探究處方對低溶解度藥物吸收的影響-環丙沙星


Use of Modeling and Simulation Tools for Understanding the Impact of Formulation on the Absorption of Low Solubility Compound: Ciprofloxacin.

Martinez M, Mistry B, Lukacova V, Polli J, Hoag S, Dowling T, Kona R, Fahmy R. AAPS J. Apr 26. IF=3.737


29.   開發和驗證雌二醇經皮給藥系統的體內外相關性IVIVC模型


Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems.

Yang Y, Manda P, Pavurala N, Khan MA, Krishnaiah YS. (2015).

J Control Release. May 13;210:58-66. IF=7.727


30.   生理學吸收模型在安非他命鹽型藥品的仿制藥評價中的應用


Application of Physiologically Based Absorption Modeling for Amphetamine Salts Drug Products in Generic Drug Evaluation.

Babiskin AH, Zhang X. (2015). J Pharm Sci. May 13. IF=2.997


31.   利培酮微球注射劑的體內外相關性IVIVC模型


In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.

Shen J, Choi S, Qu W, Wang Y, Burgess DJ. (2015) J Control Release. Sep 28;218:2-12. IF=7.727


32.   通過建模與模擬研究質子泵抑制劑PPI對鎂離子吸收的影響

Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis: part I. oral absorption of magnesium.

Bai JP, Hausman E, Lionberger R, Zhang X. (2012) Mol. Pharmaceutics 2012, 9, 12, 3495–3505. IF=4.321


33.   使用體內外相關性IVIVC預測幾種BCS 1類藥物緩釋骨架片的PK


Use of In Vitro-In Vivo Correlation to Predict the Pharmacokinetics of Several Products Containing a BCS Class 1 Drug in Extended Release Matrices.

Mirza T, Bykadi SA, Ellison CD, Yang Y, Davit BM, Khan MA. (2012)Pharm. Res. Aug. 22. IF=3.242


34.   具有預測性的生物藥劑學建模和模擬方法在藥物開發和法規監管評估中的作用


The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation.

Jiang W, Kim S, Zhang X, Lionberger RA, Davit BM, Conner DP, Yu LX. (2011) Int J Pharm. 418(2):151-60. IF=4.845


35.   藥物開發階段,采用基于生理學的吸收模型實施質量源于設計QbD


Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development.

Zhang X, Lionberger RA, Davit BM, Yu LX. (2011) AAPS J. 13(1):59-71.IF=3.737


36.   生理藥代動力學PBPK建模與模擬在法規監管審評中的應用


Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review.

Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, et al. (2011)Clin Pharmacol Ther. 89(2):259-67. IF=6.565


37.  整合生命階段的生理藥代動力學PBPK模型與不良結果通路(AOPs)和環境暴露模型,以篩選對環境的危害


Integration of Life-Stage Physiologically-Based Pharmacokinetic (PBPK) Models with Adverse Outcome Pathways (AOPs) and Environmental Exposure Models to Screen for Environmental Hazards.

El-Masri H, Kleinstreuer N, Hines RN, Adams L, Tal T, Isaacs K, Wetmore BA, Tan YM. (2016). Toxicol Sci. May 4. IF=3.703


38.   使用高通量的體外數據,高通量暴露模型,生理藥代動力學/藥效模型,估算甲狀腺過氧化物酶抑制劑的體內暴露


Estimating Margin of Exposure to Thyroid Peroxidase Inhibitors Using High-throughput In Vitro Data, High-throughput Exposure Modeling, and Physiologically-Based Pharmacokinetic / Pharmacodynamic Modeling.

Leonard JA, Tan YM, Gilbert M, Isaacs K, El-Masri H. (2016) Toxicol Sci. Feb 10. IF=3.703


點擊查看其他文獻


  • GastroPlus在PBPK、ACAT、PBBM模型應用的綜述文章(2011-2020)

  • 采用GastroPlus預測PK曲線或PK參數的應用文章(2011-2020)

  • GastroPlus在口服吸收、制劑開發等的應用文章(2011—2020)

  • GastroPlus在IVIVC, IVIVR, BE考察的應用文章(2012—2020)

  • GastroPlus在PK-PD結合模型的應用文章(2012—2020)

  • GastroPlus在預測特定人群PK的應用文章(2011—2020)

  • GastroPlus在預測藥物相互作用DDI的應用文章(2011 —2020)

  • GastroPlus在考察食物效應的應用文章(2013—2020)

  • GastroPlus在考特殊給藥途徑的應用文章(2012—2020)

  • GastroPlus在毒理領域的應用文章(2012年—2020年10月)

  • 評估GastroPlus預測準確性的應用(2011年—2020年 10月)

  • 中國用戶采用GastroPlus發表的應用文章(2013年—2020年10月)





  • 上一頁: 沒有了!
  • 下一頁: GastroPlus 在PBPK、ACAT、PBBM 模型應用的綜述文章(2011-2020)
logo
  • 上海市
  • 021-50263208
  • 客服微信:ipharmogo

快捷導航

  • 關于我們
  • 新聞資訊
  • 產品中心
  • 培訓中心
  • 在線申請
  • 聯系我們

關注公眾號
了解更多資訊

Copyright ? 2018-2021 上海凡默谷信息技術有限公司 All Rights Reserved.    

電話咨詢
產品中心
新聞資訊
QQ客服
久久中文字幕人妻熟女22页,久久综合中文字幕无码,亚洲欧美日韩综合俺去了,小泽玛利亚一区二区免费